Australia markets closed

Clarus Therapeutics Holdings, Inc. (CRXT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.5000-0.0800 (-5.06%)
At close: 04:00PM EST
1.5000 0.00 (0.00%)
After hours: 07:17PM EST

Clarus Therapeutics Holdings, Inc.

555 Skokie Boulevard
Suite 340
Northbrook, IL 60062
United States
847 562 4300
https://www.clarustherapeutics.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Robert E. Dudley Ph.D.Founder, Pres, CEO & Director557.6kN/A1955
Mr. Steven A. Bourne CPAChief Admin. Officer & Sec.410.83kN/A1962
Mr. Frank A. Jaeger M.A., M.B.A.Chief Commercial Officer414.23kN/A1970
Mr. Richard Dale PetersonChief Financial OfficerN/AN/A1968
Mr. Steve StarkVP of Commercial Analytics & OperationsN/AN/AN/A
Ms. Kara J. StancellVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. LaTonya WrightVP of SalesN/AN/AN/A
Ms. Rozita PassarellaVP of MarketingN/AN/AN/A
Dr. Jay Newmark M.B.A., M.D.Chief Medical OfficerN/AN/AN/A
Mr. James HollowaySr. VP of Manufacturing & SupplyN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

Corporate governance

Clarus Therapeutics Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.